Company Overview

Update
Founded:
2006
Headquarters:
Bridgewater, NJ
Funding:
$6.50M
Categories:
Biotechnology

CorMedix is a specialty pharmaceutical company that develops products for the treatment of cardiac, renal and infectious diseases.

Description

Update

CorMedix Inc. is a specialty pharmaceutical company that develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Specifically, our goal is to treat human disease by reducing commonly associated renal, cardiovascular, metabolic and infectious complications. Our therapeutic candidates may be small molecules, biologics, chemical entities, devices and/or diagnostics (molecular/lab tests) that enable targeted therapy in these areas.

CorMedix has received CE Mark approval for Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Our goal is to provide risk mitigation solutions for central venous catheters (CVCs) in a variety of important indications.

Current Team (3)

Update

Funding Rounds (3) - $6.50M

Update

Offices/Locations (1)

Update
  • Office

    745 Route 202-206, Suite 303

    Bridgewater, NJ 08807

    USA

Images (1)

Update
  • 9adc46d75cde39d64ce7f9d744bd42bf